Home > Newsletters > RxTrials Institute Drug Pipeline Alert > Drug Supports Tolerability Profile for Treatment of Multiple Cancers
RxTrials Institute Drug Pipeline Alert
Nov. 5, 2008 | Vol. 6 No. 45
Drug Supports Tolerability Profile for Treatment of Multiple Cancers
Celldex Therapeutics’ Phase I clinical trials of its cancer vaccine candidate, CDX-1307, combined with a protein, GM-CSF, showed encouraging results.
The open-label, dose-escalating studies evaluated the safety and immunogenicity of the drug alone and in combination with GM-CSF in patients with incurable breast, bladder, pancreatic or colorectal cancer. The drug was well tolerated, providing a basis for further testing in combination with more potent adjuvants, Celldex said.
The company expects more data in the first half of 2009.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.